The recent approval of OZEMPIC reinforces the growing trend of GLP-1 drugs being used for conditions beyond diabetes and weight loss. Novo Nordisk’s blockbuster GLP-1 medication, OZEMPIC, has secured another label expansion, as the FDA has now approved it for treating chronic kidney disease.
The approval for chronic kidney disease (CKD)—a first among GLP-1 receptor agonists—positions OZEMPIC as the most widely indicated drug in its class. Initially approved in 2017 for glycemic control in type 2 diabetes, OZEMPIC later received FDA approval in 2020 to reduce the risk of major adverse cardiovascular events in adults with T2D and established cardiovascular disease. T...
